AC Immune SA EBITDA 2011-2026 | ACIU

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA AC Immune SA

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-79 M	-61.3 M	44.5 M	-49.6 M	-22.5 M	-10.2 M	18.9 M	11 M	-	-	-

All numbers in CHF currency

Indicator range from annual reports

Maximum	Minimum	Average
44.5 M	-79 M	-18.5 M

Quarterly EBITDA AC Immune SA

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-14.5 M	-12.2 M	-11.6 M	-11.3 M	3.19 M	-9.64 M	-8.25 M	-7.83 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in CHF currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
3.19 M	-14.5 M	-9.01 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
ACADIA Pharmaceuticals ACAD	232 M	$ 22.5	1.86 %	$ 3.73 B	USA
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
AlloVir ALVR	-46.1 M	-	4.14 %	$ 49.1 M	USA
Alnylam Pharmaceuticals ALNY	557 M	$ 327.16	2.39 %	$ 42.9 B	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Amgen AMGN	14.2 B	$ 349.22	2.71 %	$ 188 B	USA
Amphastar Pharmaceuticals AMPH	172 M	$ 20.4	-0.87 %	$ 954 M	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Aquestive Therapeutics AQST	-70.5 M	$ 4.18	1.33 %	$ 447 M	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Arcutis Biotherapeutics ARQT	-11.5 M	$ 24.57	5.59 %	$ 3.13 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Autolus Therapeutics plc AUTL	-262 M	$ 1.48	8.46 %	$ 394 M	Britain
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.85	2.41 %	$ 9.26 B	Australia
BioNTech SE BNTX	15.3 B	$ 91.76	2.39 %	$ 27.2 B	Germany
CymaBay Therapeutics CBAY	-101 M	-	-	$ 3.45 B	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Aytu BioScience AYTU	-2.45 M	$ 2.71	5.51 %	$ 17 M	USA
Avid Bioservices CDMO	-7.57 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	-176 M	-	-	$ 1.41 B	USA
Can-Fite BioPharma Ltd. CANF	-10.1 M	$ 3.06	0.99 %	$ 6.66 B	Israel
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Cabaletta Bio CABA	-171 M	$ 3.06	-0.33 %	$ 307 M	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Cerus Corporation CERS	-7.26 M	$ 1.9	2.99 %	$ 362 M	USA
Coherus BioSciences CHRS	-180 M	$ 1.7	1.8 %	$ 199 M	USA
CollPlant Biotechnologies Ltd. CLGN	-16.2 M	$ 0.36	0.28 %	$ 4.12 M	Israel
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	-76 M	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Catalyst Pharmaceuticals CPRX	258 M	$ 25.57	2.3 %	$ 3.13 B	USA
CTI BioPharma Corp. CTIC	-77.8 M	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	22 K	-	-45.71 %	$ 1.2 M	Canada
Cyclacel Pharmaceuticals CYCCP	-8.42 M	-	-4.36 %	$ 27 M	USA
Cellectar Biosciences CLRB	-22.8 M	$ 2.81	2.18 %	$ 7.33 M	USA
Deciphera Pharmaceuticals DCPH	-209 M	-	-	$ 2.18 B	USA